1/21/2010

A survey by Tufts University found that the number of treatments that received orphan-drug designation from the FDA increased from 208 products between 2000 and 2002 to 425 between 2006 and 2008. The data highlight pharmaceutical companies' growing interest in drugs for rare diseases, according to the study.

Full Story:
MSNBC

Related Summaries